In sud­den re­vamp, Cel­gene CEO Alles bids his COO good­bye and looks to re­gain con­fi­dence with man­age­ment shuf­fle

8 years ago
People

As­traZeneca hands Com­pu­gen $10M to launch I/O dis­cov­ery deal; RA Cap­i­tal joins op­po­si­tion to pro­posed BioCryst/Idera ...

8 years ago
News Briefing

Tired of fin­ish­ing in last place, Eli Lil­ly’s new R&D chief wants to shake things up

8 years ago
R&D

Backed by gi­ants, an­tibi­otics up­start Macrolide gets $20M and an ex-No­var­tis ex­ec as CEO

8 years ago
People
Financing

In sal­vage ef­fort, Sel­l­as cher­ry picks some pos­i­tive mid-stage can­cer vac­cine da­ta

8 years ago
R&D

Bounc­ing back, Med­i­ci­No­va makes big gains af­ter tout­ing triglyc­eride da­ta from a tiny study

8 years ago
R&D

Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

8 years ago
Publisher's note
Peer Review

FDA dis­miss­es Alk­er­mes’ pitch on ‘5461, de­mand­ing new de­pres­sion tri­als in a dam­ag­ing set­back

8 years ago
Pharma

The 2-tri­al hur­dle for drug ap­provals is steadi­ly los­ing ground. Are we de­valu­ing the in­dus­try's R&D gold stan­dard?

8 years ago
Bioregnum
Opinion

Watch out Al­ny­lam/Io­n­is: Pfiz­er’s pos­i­tive PhI­II tafamidis da­ta makes drug a new ri­val

8 years ago
R&D

Am­gen vet Marc de Garidel takes the helm at Cor­vidia; Pe­ter Green­leaf lands next CEO job at Cere­cor; Ed­ward Gu­daitis ...

8 years ago
Peer Review

Med­i­ci­No­va flops in PhII metham­phet­a­mine de­pen­dence tri­al, stock slips

8 years ago
R&D

Faced with fresh con­cerns about Hem­li­bra’s safe­ty, Roche spells out what it knows about 5 deaths

8 years ago
R&D

Tiny Redx slammed af­ter first pa­tient is hit by ad­verse events, forc­ing a halt to can­cer drug study

8 years ago
R&D

Eye­ing growth in re­gen­er­a­tive med­i­cine, Fu­ji­film spends $800M on two new mem­bers of its CD­MO busi­ness

8 years ago
Deals
Outsourcing

Unum Ther­a­peu­tics stum­bles on its Nas­daq de­but, rais­ing $69M and some trans­paren­cy is­sues

8 years ago
Financing

Af­ter a makeover and hir­ing spree, Chi­na's drug agency is romp­ing and stomp­ing on new re­views and ap­provals

8 years ago
China
Pharma

Could Take­da pull off a $50B-plus Shire takeover? Maybe, but an­a­lysts and in­vestors have their doubts if they should

8 years ago
Deals
Pharma

Glob­al CRO WuXi AppTec looks to raise $900M-plus from Shang­hai IPO; Edge shares crushed on PhI­II fail­ure

8 years ago
News Briefing

In a bit­ter brawl, Arc­turus de­tails ex-CEO's al­leged mis­con­ducts in law­suit and open let­ter

8 years ago
People
Pharma

Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

8 years ago
R&D

Ele­phants can't jump? IDEA's Mike Rea says some Big Phar­ma play­ers are crush­ing old be­liefs

8 years ago
R&D
Special

Ver­sant-backed Tem­pest grabs a $70M round with plans to dri­ve a slate of I/O drugs in­to the clin­ic

8 years ago
Financing

Shire shares rock­et up af­ter Take­da says it's pon­der­ing a takeover bid

8 years ago
Deals
First page Previous page 1050105110521053105410551056 Next page Last page
A service from the Financial Times